Be patient and wait for ORTX to break the downward sloping trendline. When this happens, take a Bullish Position. The uptrend should last longer than the downtrend Line.
Highly Speculative but potentially Highly rewarding.
After being battered down over the past two years ORTX may be finally poised for a long term breakout
Multiple treatment approvals in their pipeline with approval of 2 drugs in Europe - possible approval in US could catalyze this bullish formation in the following months
ORTX has a few bullish signs that make me want to go long on it:
- Broke out of a negative trend on 6th Jan
- Golden Cross formation on 8th Jan (EMA 20 crossing EMA 100 in upward trend)
- Currently forming the handle of the cup with handle pattern
- Positive MACD on daily and weekly time frames
On top of that, ORTX has strong fundamentals and growth - something...
Stock broke out from its long lasting bottoming cycle. Analysts raise guidance showing significant upside. A lot of bagholders from the past, so significant selling pressure to be expected. Volume and volatility decreased the breakout following a typical triangle. Worth observing which direction the price moves when the volume is back in the market, but i am long...
is engaged in the development of gene therapies for rare, frequently terminal, diseases, including neurometabolic disorders, primary immune deficiencies, and blood disorders. The gene therapy approach uses blood stem cells to deliver corrected genetic information directly into the patient’s body.
Orchard’s pipeline demonstrates the diversity of disorders amenable...
Orchard Therapeutics Announces Clinical Data Presentations at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) taking place virtually from August 29 - September 1, 2020.
New interim data from OTL-203, an investigational gene therapy for the treatment of mucopolysaccharidosis type I (MPS-I), will be shared as part of an...